Riskpilot← Back to searchSign inGet full accessUrologspecialisten Skåne AB
ABActiveOrg 5569287161Skeppsgatan 42Medical specialists activities · NACE 8622Est. 20130 employees
Revenue 2024
SEK 4,6M
-27% vs 2023
EBITDA margin
43.7%
-68% vs 2023
Equity ratio
42.9%
Financial strength
Net profit 2024
SEK 1,7M
-62% vs 2023
| Revenue | SEK 4,6M | -27% |
| EBITDA | SEK 2M | -68% |
| Net profit | SEK 1,7M | -62% |
| Total assets | SEK 4,2M | -81% |
| Equity | SEK 1,8M | -91% |
| Employees | 0 | — |
Legal name
Urologspecialisten Skåne AB
Org number
5569287161
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
12 april 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Hälso- och sjukvård, utbildning, föreläsningar, idrottsmedicin, försäljning av medicinsk utrustning, marknadsföring, pr, journalistik, kapitalförvaltning och närliggande verksamheter.
Address
Skeppsgatan 42
Email
ulf.k.hakansson@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 667 | 6 067 | 6 211 | 6 222 | 4 567 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 4 004 | 4 064 | 3 969 | 6 156 | 1 994 |
| Depreciation & amort. | −178 | −178 | −178 | −249 | −6 |
| EBIT | 3 826 | 3 886 | 3 791 | 5 907 | 1 988 |
| Net financials | −3 | 2 | 2 | −479 | 160 |
| Profit before tax | 3 823 | 3 887 | 3 793 | 5 283 | 2 148 |
| Tax | −890 | −877 | −863 | −796 | −426 |
| Net profit | 2 933 | 3 010 | 2 930 | 4 487 | 1 722 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 13 588 | 16 596 | 19 221 | 21 920 | 4 158 |
| Equity | 10 397 | 12 988 | 15 405 | 19 317 | 1 785 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 604 | 686 | 543 | 723 | 654 |
| Total debt | 604 | 686 | 543 | 723 | 654 |
EBITDA margin
43.7%
This company
15.8%
Market median
+177% vs market
20202024
Equity ratio
42.9%
This company
38.2%
Market median
+12% vs market
20202024
Return on equity
96.5%
This company
18.4%
Market median
+424% vs market
20202024
Net profit margin
37.7%
This company
8.1%
Market median
+365% vs market
20202024
Asset turnover
1.10×
This company
1.12×
Market median
+2% vs market
20202024
Debt / equity
1.33×
This company
0.62×
Market median
-115% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
UK Chief Executive Officer | Chief Executive Officer | 2021 |
JF | Audit | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Urologspecialisten Skåne AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Krister Håkansson | Chief Executive Officer | 0 companies |
| Johan Fredrik Henriksson | Audit | 0 companies |
| Ella Margareta Ulfsdotter Håkansson | Deputy Board Member | 0 companies |
| Ottilia Astrid Ulfsdotter Håkansson | Deputy Board Member | 0 companies |
| Sara Margareta Håkansson | Deputy Board Member | 0 companies |